Medacta Posts 9.7% H1 2026 Revenue Surge, Defying Global Orthopedic Headwinds

Medacta Delivers Resilient First-Half Performance in 2026

Medacta Group SA, a globally renowned Swiss developer of joint replacement, spine surgery, and sports medicine devices, has officially released its financial figures for the first half of 2026. The company successfully defied macroeconomic hurdles and localized market softness to post group revenues of €368 million. This translates to a 9.7% year-over-year growth rate in constant currency terms, or 7.0% when reported in actual Euros.

Executive leadership emphasized that this performance was built on top of an exceptionally strong comparable baseline from the previous year. By continuously expanding its clinical footprint and deepening surgeon relationships through specialized medical education initiatives, Medacta has managed to consistently outpace broader orthopedic market averages.

Drivers of Growth: Innovation and Global Expansion

The stellar performance across the board was propelled by solid gains in core business lines and diverse geographic regions. Key highlights of the first semester include:

• Knee Segment Expansion: Knee revenues climbed 10.8% in constant currency to €154 million, driven by strong adoption in EMEA and the Asia-Pacific region.
• Hip Solutions Performance: Hip revenues advanced 8.1% in constant currency to reach €145 million, supported by ongoing demand for the proprietary AMIS platform and cutting-edge implant tech.
• Geographic Outperformance: Latin America led regional growth at 16.4%, followed closely by Asia-Pacific at 13.1% and EMEA at 10.0%, offsetting a more modest 6.6% rise in North America.

On the profitability front, Medacta recorded a solid adjusted EBITDA of €97 million, translating to a robust constant-currency margin of 27.8%. While net profit declined to €41.9 million from €60.0 million in the prior-year period—primarily due to a €14 million one-off bargain purchase gain recorded in H1 2025—underlying operational efficiency remained remarkably high.

Strategic Capital Allocation and Supply Chain Enhancements

To support its long-term scaling strategy, Medacta is actively investing in global infrastructure. The company has initiated operations at its fully automated warehouse in Cermenate, Italy, designed to compress handling and logistics costs across Southern Europe. Meanwhile, construction on its manufacturing hub in Ticino, Switzerland, remains on schedule.

Crucially for North American operations, Medacta secured land in Tennessee, USA, slated for a multi-phase development project involving up to $85 million in capital expenditures over the next five years. This move aims to insulate supply chains and aggressively expand localized manufacturing capacity.

Market Implications and What Investors Should Watch

For institutional investors and healthcare analysts, Medacta’s ability to protect margins in the high twenties while scaling operations is a significant positive indicator. The ongoing transition of the U.S. spine sales channel temporarily restrained North American growth, but management anticipates that the rollout of NextAR 2.0 and new shoulder and sports medicine applications will fuel a stronger second half.

Looking ahead, Medacta reaffirmed its full-year 2026 revenue growth guidance of 10% to 14% in constant currency, alongside an expected 50 basis point expansion in adjusted EBITDA margin. Investors should closely monitor the execution of the U.S. facility buildout, the market uptake of the NextAR ecosystem, and ongoing sales force optimization strategies as catalysts for hitting mid-term compound annual growth rate targets.